컨퍼런스 커버리지 | 학술센터 | 킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

66th American Society of Hematology Annual Meeting and Exposition (ASH 2024)

07 Dec -10 Dec, 2024, United States OLD

Acalabrutinib-venetoclax hits mark for fit TN CLL patients

2025-01-10

The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naive (TN) chronic lymphocytic leukaemia (CLL).
Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

2025-01-10

In the final 2-year analysis of the EBMT-SAAWP* RACE** study, the addition of eltrombopag to standard immunosuppressive treatment (IST) comprising horse antithymocyte globulin (hATG) plus cyclosporin A (CsA) improves long-term outcomes as frontline therapy for severe aplastic anaemia/very severe aplastic anaemia (SAA/vSAA).
Blinatumomab plus chemo improves survival in paediatric B-ALL

2025-01-10

Chemotherapy combined with blinatumomab (blin) delivers significant improvements in disease-free survival (DFS) in children with newly diagnosed National Cancer Institute standard risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL), according to the results of the AALL1731 study presented at ASH 2024.
Consolidative stem cell transplant may be skipped for MCL patients with undetectable disease

2025-01-10

In patients with mantle cell lymphoma (MCL) who have achieved complete remission and undetectable minimal residual disease (MRD) following initial therapy, autologous hematopoietic cell transplantation (auto-HCT) confers no survival advantage when compared with maintenance therapy alone, as shown in the interim results of the phase III ECOG-ACRIN EA4151 trial.
Hydroxyurea for HbSC tied to fewer vaso-occlusive events, hospitalizations

2025-01-10

Treatment with hydroxyurea at 20 mg/kg/day results in significantly fewer painful vaso-occlusive events and fewer hospitalization in patients with haemoglobin (Hb) sickle cell (HbSC) disease, indicating its effective disease-modifying effect. It is also well-tolerated in both children and adults with HbSC.
Mitapivat cuts transfusion burden in TD thalassaemia

2025-01-10

In adults with transfusion-dependent (TD*) α- or β-thalassaemia, mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, significantly reduces transfusion burden, with durable responses up to 36 weeks, findings from the phase III ENERGIZE-T study have shown.
Overall outlook for paediatric sickle cell disease improved with stem cell transplant

2025-01-10

Allogeneic stem cell transplantation (allo-SCT) appears to confer lasting benefits to children with sickle cell anaemia and a history of abnormal cerebral velocities, with substantial improvements in quality of life (QoL) and cognitive outcomes 10 years later, according to the results of the DREPAGREFFE-2 trial.
Rilzabrutinib delivers beneficial effects in immune thrombocytopenia

2025-01-10

A phase III trial (LUNA 3) has demonstrated robust therapeutic effects for rilzabrutinib in patients with previously untreated immune thrombocytopenia (ITP). Use of this BTK inhibitor results in rapid and durable platelet response, reduced bleeding and need for rescue therapy, improved physical fatigue and quality of life (QoL), and favourable safety and tolerability.
Tafasitamab plus lenalidomide, rituximab boosts PFS in follicular lymphoma

2025-01-10

The addition of tafasitamab (tafa) to lenalidomide and rituximab (len+R) significantly improves progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL), as shown in a phase III study presented at ASH 2024. The safety profile of this combination is manageable and consistent with expected toxicities.

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브